Horizon Health International Corp.

September 17, 2010 15:50 ET

Horizon Health International Corp. Requests FDA Label Approval for Fat Burning & Metabolic Regulation

MONTREAL, QUEBEC--(Marketwire - Sept. 17, 2010) - HORIZON HEALTH INTERNATIONAL CORP. (PINK SHEETS:HZHI) (the Company) is pleased to announce the FDA Label application of Enteric Lactoferrin.

Mr. Rocco Di Fruscia, President of Horizon Health International Corp., an emerging specialty pharmaceutical company is pleased to announce that NRL Pharma Canada Inc. has requested FDA Label approval of the claims in the US Patent Application Number 20080014270 to commercialize this application for treatment of Fat Burning and Metabolic Regulation.

It is estimated between $33 billion and $55 billion is spent annually on weight loss products and services, including medical procedures and pharmaceuticals, with weight loss centers garnering between 6 percent and 12 percent of total annual expenditure. About 70 percent of Americans' dieting attempts are of a self-help nature. Although often short-lived, these diet fads are a positive trend for this sector as Americans ultimately turn to professionals to help them meet their weight loss goals.

Furthermore the NRL Pharma Canada Inc plans to raise capital to commence clinical trials in the USA to support the following claims in the Patent application it is useful for treating hypercholesterolemia, hyper-neutral lipidemia, hyper-low density lipoprotein (LDL) cholesterolemia, hypo-high density lipoprotein (HDL) cholesterolemia, obesity, fatty liver and cholesterol gallstone and lifestyle-related diseases such as severe obesity.

Mr. Di Fruisca says: "The individuals who have been taking our Enteric Lactoferrin, have given us nothing but positive feedback and are highly satisfied with their results."

The Company's business:

HORIZON's Subsidiary 'New Release Lactoferrin Pharma Canada Inc.' is an emerging specialty pharmaceutical company that is committed to supply its Patented delivery systems of enteric lactoferrin, and "PEG-lactoferrin", We have already introduced enteric lactoferrin products in the market as a supplemental food and have also undertaken projects to further study these products and increase their pharmaceutical applications. Since 2008, the company's proprietary enteric lactoferrin has already earned top market share amongst all lactoferrin-containing products.

Forward-looking statements in this release are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties, including, without limitation, continued acceptance of the Company's products, increased levels of competition, new products and technological changes, dependence upon third-party suppliers, intellectual property rights, and other risks detailed from time to time in the Company's periodic reports.

Contact Information